BGH Capital quietly announced the $2.4 billion acquisition of Aspen Pharmacare’s Asia Pacific business in the final days of 2025. Now, its dealmakers, led by co-founder Robin Bishop, have hit the pavement to find co-investors.
Street Talk understands the $6.8 billion Melbourne private equity firm has begun reaching out to its existing institutional limited partners to invest alongside it. BGH had co-investors committed before it signed the deal. However, it’s now looking to syndicate a small amount, less than 5 per cent of Aspen APAC’s enterprise value, to some of its backers who couldn’t dot the i’s and cross the t’s in the lead-up to Christmas.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com